Theolytics

Join us as we welcome David Apelian MD, PhD, MBA as CEO to Theolytics. David brings significant corporate, clinical development, and regulatory experience and joins us we advance our first clinical trial in ovarian cancer with lead candidate THEO-260. To read more about David and the appointment: https://lnkd.in/ePybPa6D #OncolyticImmunotherapy #OvarianCancer #BiotechCEO

Today we announce that we have dosed the first patient in our Phase I/IIa trial of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer. THEO-260 is uniquely positioned to tackle the complex, immune supressed nature of advanced solid tumours.   This is a major milestone for Theolytics and brings us closer to delivering effective new treatment options for the many women who suffer from ovarian cancer, one of the leading causes of cancer-related deaths among women.   Read the full announcement: https://lnkd.in/ew26JC_B #OvarianCancer #ImmunoOncology #OncolyticImmunotherapy  

Delighted to support The Curiosity Box in their encouragement of scientists and engineers of the future. Good luck and thank you to both you and Larkrise Primary School School for the opportunity to help with your valuable work #stemcareers #scienceinschools #biotech

Join our CSO Margaret Duffy at #SITC2024 as she presents the latest on our lead candidate THEO-260, developed for Ovarian Cancer. THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovarian cancer and other solid tumours. We are excited to share the latest from Theolytics and the opportunity to connect with other innovators in the Cancer Immunotherapy space. #SITC2024 #SITC #CancerResearch #Immunotherapy #ImmunoOncology #OncolyticImmunotherapy #Theolytics

📣We are looking for a Senior Technician to join our team📣 🌟At Theolytics we are developing next-generation cancer therapies. Our lead program is a next-generation oncolytic adenovirus being developed for ovarian cancer 🌟 🥼This is a crucial, lab based role to help support us in our next phase as we transition to a clinical-stage company ❔Think this could be for you? We’d love to hear from you 📝Apply now and join us on our exciting journey! https://lnkd.in/eCwfVVkH

We are proud to share that we have been awarded funding from Innovate UK’s Transforming Cancer Therapeutics Grants Call to support the advancement of next-generation immunotherapies for cancer. Looking forward to another great collaboration with Innovate UK! #oncolyticvirus #cancerimmunotherapy #ovariancancer #ukbiotech https://lnkd.in/ePgUm49k

Today we say a fond farewell and thank you to Charlotte Casebourne Stock, Co-Founder and CEO, as she moves on to her next entrepreneurial endeavor. At Theolytics; she has built a fantastic team founded on great science with an exciting program poised to move into the clinic this year.  Charlotte will transition into an advisory role with the company, stepping down as CEO. Mike Grey, Executive Chair, will assume overall leadership responsibility until further notice. Full details: https://lnkd.in/eSis-t2g

📣We are seeking a Senior Scientist Bioassay Validation to join our team📣 🌟At Theolytics we are developing next-generation cancer therapies. Our lead program is a next-generation oncolytic adenovirus being developed for ovarian cancer. 🥼We are looking for a Bioassay Validation Specialist Senior Scientist, with a good understanding of GCLP requirements, to join our team. 🎯This position represents an excellent opportunity for someone looking to take responsibility in a fast-paced environment, working within an interdisciplinary team to develop new cancer treatments. ❔Think this could be for you? We’d love to hear from you! 📝Apply now and join us on our exciting journey! #Bioassayvalidation #Biomarker #Hiring #OxfordBiotech #GCLP https://lnkd.in/gFpmWTZ3

📣We are seeking a Senior Scientist Bioassay Validation to join our team📣 🌟At Theolytics we are developing next-generation cancer therapies. Our lead program is a next-generation oncolytic adenovirus being developed for ovarian cancer. 🥼We are looking for a Bioassay Validation Specialist Senior Scientist, with a good understanding of GCLP requirements, to join our team. 🎯This position represents an excellent opportunity for someone looking to take responsibility in a fast-paced environment, working within an interdisciplinary team to develop new cancer treatments. ❔Think this could be for you? We’d love to hear from you! 📝Apply now and join us on our exciting journey! #Bioassayvalidation #Biomarker #Hiring #OxfordBiotech #GCLP https://lnkd.in/gFpmWTZ3

Today, May 8th, is World Ovarian Cancer Day. There is a clear need for new therapies to support everyone impacted by ovarian cancer and at Theolytics we strongly support the theme of “No Woman Left Behind”. We are working hard towards our goal to develop innovative new treatment options for women with ovarian cancer, including our lead candidate THEO-260 which is set to enter the clinic this year. Together, we hope to create an impact and contribute to a future where no woman has to fear this disease.   #NoWomanLeftBehind #WOCD2024 #WorldOvarianCancerDay #CancerImmunotherapy #OvarianCancer #Oncolyticvirus